Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

Bristol-Myers Squibb38,122 enrolled

Overview

The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.

Actual number of patients enrolled for UK : 15242 patients Actual number of patients enrolled for Germany : 22880 patients

Study Type

OBSERVATIONAL

Enrollment

38,122

Conditions

Non-valvular Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have an apixaban, rivaroxaban, dabigatran or VKA prescription during the study period * Are ≥18 years old at index date * Have ≥12 months of computerised medical data prior to index date * Have a record of AF on or ever prior to index date (index OAC prescription) Exclusion Criteria: * Have a record for a valvular condition (ie, rheumatic valvular disease and prosthetic valves) on or ever prior to index date * Have a history (ever prior to index date) of the Oral anticoagulant (OACs) which are prescribed during the study period

Outcomes

Primary Outcomes

Persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation(NVAF)

We defined non-persistence in the databases as the absence of index prescription for twice the median prescription duration; and calculated cumulative incidence (95% CIs) of persistence at the end of follow-up and at different time points after treatment initiation (3, 6, and 12 months)

Time frame: 23 months for the UK and Germany, 25 months for France

Secondary Outcomes

Demographic characteristics (Age, Gender, Smoking status, region of practice, data source) of patients with newly prescribed oral anticoagulants

Time frame: 23 months for the UK and Germany, 25 months for France

Clinical characteristics (History of bleeding, myocardial infarction, stroke, Thromboembolism, congestive heart failure, vascular disease, hypertension, CHA2DS2-VASc score, HAS-BLED score, etc) of patients with newly prescribed oral anticoagulants

Time frame: 23 months for the UK and Germany, 25 months for France

Adherence to newly prescribed oral anticoagulants based on Medication possession ratio (MPR)

Time frame: 23 months for the UK and Germany

Compare persistence rates across oral anticoagulant therapies

Time frame: 23 months for the UK and Germany, 25 months for France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.